In HPD mice, large tumors treated with the triple regimen comprising anti-CTLA-4 antibody + cabozantinib + chidamide-HCl showed an enhanced tumor response rate and prolonged survival time, as shown in Figure 5G and Figure 6H. We observed that this treatment regimen could prevent relapse and inhibit CT-26 tumor growth in HPD mice in a rechallenge test, as shown in Table 4. The gene discussed is CTLA4; the disease is neoplasm.